Neurocrine Biosciences Announces Publication Of Positive Results From Kinect 3 Phase III Study Of INGREZZA TM (Valbenazine) For The Treatment Of Tardive Dyskinesia Post author:Sam Post published:March 20, 2017 Post category:BioPharma Life Sciences Jobs … Source: BioSpace You Might Also Like FDA Hails Novartis' Kisqali a Breakthrough January 2, 2018 Medovex Corporation Retains CG Capital As Investor Relations Counsel April 13, 2017 CryoPort Announces Proposed Public Offering Of Common Stock March 27, 2017